Comparative analysis of HER2 copy number between plasma and tissue samples in gastric cancer using droplet digital PCR
Open Access
- 6 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 10 (1), 1-8
- https://doi.org/10.1038/s41598-020-60897-4
Abstract
In this study, we measured the human epidermal growth factor receptor 2 (HER2) copy number in both tissue and plasma samples of gastric cancer patients by using droplet digital polymerase chain reaction (ddPCR) method. Eighty gastric cancer patients were enrolled and both formalin-fixed and paraffin-embedded tissue and preoperative plasma samples were collected. HER2 status was determined by HER2 immunohistochemistry (IHC)/silver in situ hybridization (SISH) in tissue samples and ddPCR of the target gene HER2 and the reference gene eukaryotic translation initiation factor 2C, 1 in both tissue and plasma. The concordance rate of tissue HER2 status determined by IHC/SISH and HER2 ddPCR was 90.0% (72/80), and the sensitivity and specificity of tissue ddPCR were 85.0% and 95.0%, respectively. The concordance rate of plasma ddPCR and IHC/SISH was 63.8% (51/80). The sensitivity, specificity, positive predictive value, and negative predictive value of plasma HER2 ddPCR were 37.5%, 90.0%, 79.0%, and 59.0%, respectively. As HER2 measurement by tissue ddPCR showed a high concordance rate with HER2 status by IHC/SISH, it could replace tissue IHC/SISH testing in gastric cancer. These findings may contribute to the development of tissue and plasma HER2 testing that would be useful in daily practice.Funding Information
- National Research Foundation of Korea (2019R1A2C1086180)
This publication has 31 references indexed in Scilit:
- HER2 testing in gastric cancer diagnosis: insights on variables influencing HER2-positivity from a large, multicenter, observational study in GermanyVirchows Archiv, 2019
- HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics CommitteeJournal of Clinical Pathology, 2018
- Molecular Testing for Gastrointestinal CancerJournal of Pathology and Translational Medicine, 2017
- Droplet digital polymerase chain reaction detection of HER2 amplification in formalin fixed paraffin embedded breast and gastric carcinoma samplesExperimental and Molecular Pathology, 2016
- Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancerGastric Cancer, 2016
- A novel gene–protein assay for evaluating HER2 status in gastric cancer: simultaneous analyses of HER2 protein overexpression and gene amplification reveal intratumoral heterogeneityGastric Cancer, 2014
- Clinical significance of intratumoral HER2 heterogeneity in gastric cancerEuropean Journal of Cancer, 2013
- HER2 testing in gastric cancer: a practical approachLaboratory Investigation, 2012
- Clinicopathologic Characteristics of Patients With Stage III/IV (M0) Advanced Gastric Cancer, According to HER2 Status Assessed by Immunohistochemistry and Fluorescence In Situ HybridizationDiagnostic Molecular Pathology, 2011
- Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease.Journal of the National Comprehensive Cancer Network, 2010